Welcome to our dedicated page for Curative Biotechnology news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on Curative Biotechnology stock.
Curative Biotechnology, Inc. (OTC: CUBT) is a development-stage biomedical company focused on novel therapies for rare diseases, with programs in degenerative eye disease, infectious disease, and neuro-oncology. The CUBT news feed on this page aggregates company-issued updates and other coverage so readers can follow how its pipeline and strategy evolve over time.
Recent news has highlighted Curative Biotech’s emphasis on its degenerative eye disease platform, built on a worldwide exclusive license from the National Eye Institute (NEI) at the NIH. Articles cover progress with its metformin-based ophthalmic reformulation for intermediate and late-stage Age-Related Macular Degeneration (AMD), including completion of IND-enabling toxicology work, a planned first-in-human trial under a CRADA with the NEI, and the filing of a PCT patent application for an ophthalmic formulation capable of delivering metformin to the choroid, RPE, and retina.
News items also describe corporate and strategic developments, such as the establishment of Curative Biotech Japan K.K. to support licensing and asset acquisitions in Japan, the engagement of Golden Eagle Capital Advisors, Inc. as exclusive agent and strategic advisor, and updates on capital structure, including withdrawal of a planned S-1 offering and revisions to a proposed reverse stock split. Governance-focused releases detail the nomination or appointment of independent directors with ophthalmology and biotechnology experience and the creation of a Clinical Development Committee of the Board.
Investors and observers can use this page to review Curative Biotech’s announcements on clinical planning, licensing strategy, veterinary ophthalmology initiatives in canine retinal diseases, and capital markets intentions, all in one place. Bookmark this feed to quickly reference historical and ongoing CUBT news as the company advances its development-stage programs.
Curative Biotechnology (OTC: CUBT) announced that the Canadian Intellectual Property Office issued a Notice of Allowance for Canadian Patent Application No. 3,151,011 titled “Druggable Target to Treat Retinal Degeneration.” Curative is the exclusive worldwide licensee under an agreement with the National Eye Institute, and the invention was developed by Dr. Kapil Bharti and team. The allowance includes 22 allowed claims covering topical ocular delivery approaches relevant to metformin-based formulations and is expected to formally issue in the coming months. The company also noted parallel development into select canine retinal indications such as PRA and PRCD.
Curative Biotechnology (OTC: CUBT) announced a strategic redirection focused on sublicensing and manufacturing partnerships, a revised reverse stock split, and withdrawal of a planned S-1 public offering.
Key actions: pursuing a sublicence/manufacturing agreement for its metformin-based eye drops; targeting simultaneous human Dry AMD and canine indications (CPRA with a single 24-dog accelerated trial; PRA with ~300-dog effectiveness trial); withdrawing the S-1; and approving a 150-to-1 reverse split (replacing 400-to-1) pending FINRA approval. The company also plans to apply to uplist to the OTCQB after the sublicense and reverse split.
Curative Biotechnology (OTC: CUBT), a development-stage biomedical company specializing in treatments for degenerative eye diseases, has announced the appointment of Golden Eagle Capital Advisors (GECA) as its exclusive agent and strategic advisor. GECA, a Dubai-based financial advisory group, will provide strategic guidance to support CUBT's business objectives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Curative Biotechnology Inc. (CUBT) announced on January 5, 2023, the successful completion of its IND enabling Tolerance and Toxicology Study of Metformin HCL Solution for eye drop use in rabbits. This milestone allows the company to prepare its IND application for a clinical trial targeting Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA). The studies address unmet medical needs, as no FDA-approved treatments currently exist for these conditions. The first human study will be conducted under a CRADA with the National Eye Institute.
Curative Biotechnology Inc. (CUBT) announced plans for an underwritten public offering of its common stock, following a 1-for-400 reverse stock split. The offering may include a 45-day option for the underwriter to purchase an additional 15% of shares. Proceeds will be allocated for working capital and corporate purposes. The offering is subject to market conditions and is expected to close by September 30, 2022, with trading on the NYSE American set to begin on October 3, 2022. Aegis Capital Corp. is the sole book-running manager for this offering.
FAQ
What is the current stock price of Curative Biotechnology (CUBT)?
What is the market cap of Curative Biotechnology (CUBT)?
